ACER Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (20 Nov 2023 @ 15:59):

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases...

Stats
Today's Volume	574 675
Average Volume	2.39M
Market Cap	16.15M
EPS	$0 ( 2024-05-13 )
Next earnings date	( $0 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.342
ATR14	$0.0570 (8.64%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-17	Aselage Steve	Sell	483 741	Common Stock, $0.0001 par value per share
2023-11-17	Dunn John Michael	Sell	27 380	Common Stock, $0.0001 par value per share
2023-11-17	Joseph Donald	Sell	14 285	Common Stock, $0.0001 par value per share
2023-11-17	Schelling Chris	Sell	2 712 529	Common Stock, $0.0001 par value per share
2023-11-17	Palmin Harry S	Sell	125 000	Common Stock, $0.0001 par value per share

INSIDER POWER
-70.16
Last 96 transactions
Buy: 5 870 002 \| Sell: 3 622 222

Volume Correlation

Long: 0.50 (weak)

Short: -0.98 (very strong negative)

Signal:(30.163) Neutral

Acer Therapeutics Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Acer Therapeutics Inc Correlation - Currency/Commodity

0.07
( neutral )

0.12
( neutral )

0.00
( neutral )

0.05
( neutral )

-0.22
( neutral )

Acer Therapeutics Inc Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.770

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.770

FY	2021
Revenue:	$1.26M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.080

FY	2020
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-2.06

Financial Reports:

No articles found.

Acer Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Acer Therapeutics Inc

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.